Bay City Capital Completes Private Placement Financing

Represented Bay City Capital, LLC in private placement financing for Interleukin Genetics, Inc. (QTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions.

The Bay City funds acted as the lead investors in an investment syndicate comprised of Pyxis Innovations Inc., an affiliate of Alticor Inc., parent company to Amway Corporation, and New Enterprise Associates (NEA), a life sciences investment firm. Interleukin intends to use the proceeds from the financing to accelerate commercialization of its genetic tests, including PerioPredict®, which identifies genetic variations that increase the risk for severe periodontal disease, and for general corporate and working capital purposes.